WO1997026332A1 - Systeme faisant appel a un baculovirus pour l'expression d'un recepteur de l'interleukine 5 humaine et methode de criblage d'antagonistes de l'interleukine 5 - Google Patents

Systeme faisant appel a un baculovirus pour l'expression d'un recepteur de l'interleukine 5 humaine et methode de criblage d'antagonistes de l'interleukine 5 Download PDF

Info

Publication number
WO1997026332A1
WO1997026332A1 PCT/US1997/000011 US9700011W WO9726332A1 WO 1997026332 A1 WO1997026332 A1 WO 1997026332A1 US 9700011 W US9700011 W US 9700011W WO 9726332 A1 WO9726332 A1 WO 9726332A1
Authority
WO
WIPO (PCT)
Prior art keywords
receptor
chain
human interleukin
interleukin
dna encoding
Prior art date
Application number
PCT/US1997/000011
Other languages
English (en)
Inventor
Ji Zhang
Peng Wang
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corporation filed Critical Schering Corporation
Priority to AU16906/97A priority Critical patent/AU1690697A/en
Publication of WO1997026332A1 publication Critical patent/WO1997026332A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons

Definitions

  • the invention relates to an expression system for the human high affinity interleukin 5 receptor. More particularly, the invention is directed to a method of screening for interleukin 5 receptor-based antagonists using a baculovirus/Sf9 expression system.
  • IL-5 Human interleukin 5
  • IL-5 is a lineage-specific cytokine released mainly from activated T cells.
  • a number of studies have demonstrated that IL-5 is responsible for the differentiation, proliferation and maturation of eosinophils from their progenitors in the bone marrow. Saito et al., 1988, Proc. Natl. Acad. Sci. USA 85:2288-2392. Lopez etal., 1988, J. Exp. Med. 167:219-224.
  • IL-5, lnterleukin-3 (IL-3) and gran ⁇ locyte-macrophage colony- stimulating factor (GM-CSF) exhibit similar functions on eosinophils in vitro. Clutterbuck etal., 1989, Blood 73: 1504-1512. Ema etal., 1990, Blood 76:1956- 1961. However, whereas the action of human lL-5 is restricted to eosinophil and closely related basophil lineages (Sanderson, 1992 Blood 79:3101 -3109), IL-3 and GM-CSF also have activities on other hematopoietic lineages. Miyajima et al., 1993, Blood 82: 1960- 1974.
  • K d 2.5 x 10- 10 M.
  • High affinity human IL-5 receptors (h!L-5R) have been found in eosinophils and their related cell lines. Migita etal., 1991 , Cell. Immunol. 133:484-497; Ingley and Young, 1991, Blood 78:339-344.
  • the cDNAs encoding the human ⁇ -chain component (hlL-5R ⁇ ) and the human ⁇ -chain component (hlL-5 ⁇ ) have been cloned and characterized. Tavernier et al., 1991, Cell, 66:1175-1184. Murata et al., 1992, J. Exp. Med. 175:341-351. Hayashida et al., 1990, Proc. Natl. Acad. Sci. USA 87:9655-9659.
  • the ⁇ subunit is responsible for IL-5 binding specificity and is distinct from the IL- 3R ⁇ subunit and the GM-CSFR ⁇ subunit.
  • Eosinophilia is characteristic of most parasitic infections as well as other disorders including dermatoses, allergies, polyarteritis nodosa and neoplastic diseases.
  • Bronchial eosinophilia is a cardinal feature of chronic asthma. Multiple lines of evidence indicate that overexpression of IL-5 plays a crucial role in a number of eosinophil-related diseases.
  • the present method fulfills this need by providing an expression system capable of expressing high levels of high affinity human interleukin 5 receptor and methods for screening for interleukin 5 antagonists.
  • the invention provides a recombinant baculovirus comprising DNA encoding human interleukin 5 receptor ⁇ -chain and/or DNA encoding human interleukin 5 receptor ⁇ -chain, which virus is capable of expressing such DNA in a host cell.
  • the invention also provides a host cell comprising at least one recombinant baculovirus, which host cell is capable of coexpressing DNA encoding human interleukin 5 receptor ⁇ -chain and human interleukin 5 receptor ⁇ -chain.
  • the invention further provides a method for producing a cell, the membrane of which contains high levels of high affinity human interleukin 5 receptors comprising:
  • the invention provides a method for identifying interleukin 5 antagonists using an interleukin 5 receptor binding assay comprising:
  • a preferred embodiment of the invention is directed to a method of detecting interleukin 5 antagonists through the use of a scintillation proximity assay (SPA). Most preferably, the method comprises:
  • the invention is directed to a baculovirus expression system which finds use in a receptor-based IL-5 antagonist screening assay. It has been discovered that high levels of high affinity hlL-5R can be expressed in insect cells infected with at least one recombinant baculovirus comprising DNA encoding the human IL-5R ⁇ -chain and/or human IL-5R ⁇ -chain.
  • the invention is based on the discovery that functional membrane-bound hlL-5R ⁇ and ⁇ can be coexpressed as high affinity hlL-5R in insect cells, which cells can then be advantageously used in an assay to screen for compounds which inhibit binding of IL-5 to the lL-5 receptors.
  • nucleotide and amino acid sequences of hlL-5R ⁇ and hlL-5R ⁇ are known in the art.
  • the nucleotide and amino acid sequences of the hlL-5R ⁇ - chain are disclosed, for example, in EP 0475 746, EP 0492 214, Tavernier et al, 1991, Cell, 66:1175-1184, and Murata etal, 1992, J. Exp. Med. 175:341-351.
  • the nucleotide and amino acid sequences of the hlL-5R ⁇ -chain are disclosed, for example, in Hayashida etal, 1990, Proc. Natl. Acad. Sci. USA 87:9655-9659.
  • DNA constructs encoding hlL-5R ⁇ and or hlL-5R ⁇ may be of genomic or cDNA origin; for instance, they can be obtained by preparing a genomic or cDNA library and screening for DNA sequences coding for all or part of the ⁇ or ⁇ chain by hybridization using synthetic oligonucleotide probes and standard techniques. Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor, 1989.
  • the DNA constructs encoding hlL-5R ⁇ and/or hlL-5R ⁇ may also be prepared synthetically by established standard methods, e.g., in an automatic DNA synthesizer, and then purified, annealed, ligated and cloned in suitable vectors.
  • DNA constructs may be of mixed synthetic and genomic, mixed synthetic and cDNA or mixed genomic and cDNA origin prepared by ligating fragments of synthetic, genomic or cDNA, the fragments corresponding to various parts of the entire DNA construct, in accordance with standard techniques.
  • the DNA constructs may also be prepared by polymerase chain reaction using specific primers. All of these techniques are well within the skill of the art.
  • DNA constructs may contain the entire native sequence of hlL-5R ⁇ and/or ⁇ or a homologue thereof.
  • the term "homologue" is intended to indicate a natural variant of the DNA sequence encoding human IL-5R ⁇ and/or ⁇ or a variant produced by modification of the DNA sequence. Examples of suitable modifications of the DNA sequence are nucleotide substitutions which do not give rise to another amino acid sequence of the hlLR-5 ⁇ or ⁇ or nucleotide substitutions which do give rise to a different amino acid sequence and therefore, possibly, a different protein structure.
  • the cloned human IL-5R ⁇ and ⁇ cDNAs may be recombinantly expressed by molecular cloning into an expression vector containing a suitable promoter and other appropriate transcription regulatory elements, and transferred into a host cell to produce recombinant hlL-5R ⁇ and ⁇ .
  • the procedures used to ligate the DNA sequences of interest, the promoter and the terminator, respectively, and to insert them into suitable vectors containing the information necessary for replication are well known to persons skilled in this art.
  • Expression vectors are defined herein as DNA sequences required for the transcription of cloned copies of genes and the translation of their mRNAs in an appropriate host.
  • Expression vectors contemplated for use in the practice of the invention are recombinant baculoviruses.
  • Autographa califomica nuclear polyhedrosis virus (AcMNPV), the prototype virus of the family Basculovirudae, has a wide host range and infects more that 30 species of Lepidotpteran insects. Its genome consists of double ⁇ stranded, circular, super-coiled DNA approximately 128 kilobases in length. Smith and Summers, 1978, Virology, 89:517-527. Smith and Summers, 1978, J. Virol. 30:828-838. Helper-independent baculovirus expression vectors have been used for the expression of a wide variety of heterologous genes. Smith et al, 1983, J. Virol. 46:584-593. Smith et al, 1983, Mol Cell. Biol. 3:2156-2165. Such vectors are known in the art and are commercially available.
  • the recombinant baculovirus utilizes the highly expressed and regulated AcMNPV polyhedrin promoter to control the inserted foreign genes. This allows expression of prokaryotic or eukaryotic genes to produce fused or non-fused recombinant proteins.
  • An intermediate plasmid construct designated as a baculovirus transfer vector, is used to insert the gene(s) of interest into the baculovirus genome at a specific region.
  • Such transfer vectors will usually contain sequences from AcMNPV including the promoter of the polyhedrin gene and varying amounts of 5' and 3' viral DNA flanking the polyhedrin gene cloned into a high copy number bacterial plasmid.
  • the desired foreign gene sequences in the recombinant plasmid can be transferred to wild-type AcMNPV by homologous recombination within a cell transfected with both the plasmid and wild-type virus DNAs.
  • An overview of the baculovirus expression system and the methods used therein may be found in Luckow and Summers, 1988, Bio/Technology 6:47-55 and Luckow and Summers, 1988, "A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures", Texas Agricultural Experimental Station, Texas A&M University, Bulletin No. 12555, 2nd edition.
  • baculovirus expression systems were, heretofore, only widely used for producing the soluble, secreted and single polypeptide-containing proteins.
  • the host cell into which the recombinant baculovirus is introduced is an insect cell, in particular Lepidotpteran insect cells, preferably Spodoptera fr ⁇ giperda cells, more preferably an Sf9 cell line. While expression in Sf9 cells is described in detail below, one skilled in the art would recognize that other insect host cells may advantageously be used in the practice of the invention.
  • High affinity IL-5R is expressed by infecting insect cells with a recombinant baculovirus containing DNA encoding both hlL-5R ⁇ -chain and hlL-5R ⁇ -chain.
  • insect cells can be infected with a first recombinant baculovirus containing DNA encoding hlL-5R ⁇ -chain and a second recombinant baculovirus containing DNA encoding hlL-5R ⁇ -chain.
  • the infected host cells are then cultured in a suitable nutrient medium under conditions which are conductive to the expression of both the ⁇ and ⁇ DNA sequences.
  • the medium used to culture the cells may be any conventional medium suitable for growing the insect cell line.
  • Suitable media are available from commercial suppliers (e.g., medium Sf-900 II SFM available from GIBCOBRL, Cat. No. 10902-088) or may be prepared according to published recipes.
  • a major advantage of this invertebrate virus expression system over bacterial and yeast is the very abundant expression of recombinant proteins, which are in many cases antigenically, immunogen ically, and functionally similar to their authentic counte ⁇ arts.
  • baculoviruses are not pathogenic to vertebrates or plants and do not employ transformed cells or transforming elements as do the mammalian expression systems.
  • the baculovirus vector also utilizes many of the protein modification processing and transport systems that occur in higher eukaryotic cells and may be essential for the complete biological function of a recombinant protein.
  • insect cells expressing high levels of high affinity hlL-5R can be prepared by infecting insect cells with at least one baculovirus containing DNA encoding hlL-5R ⁇ -chain and or DNA encoding hlL-5R ⁇ -chain. While the assay of the invention can be used with isolated membranes expressing high affinity hlL-5R, the binding assay of the invention is preferably performed using intact cells, in particular intact SF9 cells co-expressing both the ⁇ and ⁇ subunits of the high affinity human IL-5 receptor, tt has been surprisingly discovered that insect cells expressing high affinity hlL- 5R may be use in the intact state in IL-5 receptor binding assays.
  • putative IL-5 antagonists are combined with labeled IL-5 and binding of the lL-5 to the cell is measured.
  • Potential IL-5 antagonists are defined as molecules capable of binding to the IL-5 receptor or to IL-5, thus reducing or inhibiting binding of IL-5 to the receptor. Antagonists identified in accordance with the invention are selected for further study.
  • a scintillation proximity assay is used to screen for IL-5 antagonists.
  • Scintillation proximity assays of the type contemplated for use in the practice of the invention are described in U.S. Patent No. 4,568,649.
  • SPA uses a plurality of beads or other types of support structure that are impregnated and/or coated with a scintillator or fluorescer (i.e., a material capable of excitation or fluorescence when excited by radioactive energy, such as diphenyloxazole, DPO).
  • beads may be utilized, such as poiyacrylamide, acrylamide, agarose, polystyrene, polypropylene, polycarbonate or Sepharose 4B beads (Pharmacia Fine Chemicals, Uppsala, Sweden).
  • Other shapes or types of support structures, for instance latex particles, may be used as long as ligand molecules can be covalently or otherwise attached thereto and a fluorescer integrated therewith.
  • the beads are coated with a ligand that is capable of specifically binding to a reactant of interest by covalently linking or directly attaching the ligand to the beads.
  • the beads are then mixed in a water-based solution containing the reactant that has been radiolabeled.
  • the fluorescer integrated into the bead is placed in close enough physical relationship to the reactant to allow the radiation energy emitted from the reactant to activate the fluorescer thereby causing the fluorescer to emit light energy.
  • the level of light energy emitted may be conveniently measured with a scintillation counter or other monitoring device employing a photomultipli ⁇ r tube.
  • the level of light energy produced by the fluorescer is indicative of the amount of reactant bound to the beads. Since the reactant that has not bound to the ligand is too far away from the support beads to permit the radiation energy emitted there from reaching the fluourescer, the radioactive reactant that has not bound to the ligand need not be separated from the ligand-reactant complex prior to measuring the level of light energy emitted by the fluorescer.
  • radiolabeled hlL-5 is used as the labeled reactant.
  • the radiolabeled IL-5 is biologically and chemically identical to unlabeled IL-5, with the exception that the labeled reactants emit radioactive energy due to the decaying of the radioactive isotope present.
  • the technique used for labeling of the reactant varies with the type of radioactive isotope employed. For instance, labeling can be accomplished by replacing one of the atoms of the reactant molecules with a corresponding radioactive isotope.
  • a hydrogen atom could be replaced with tritium, 3 H; a carbon atom replaced with carbon-14, 14 C; or a strontium atom replaced with strontium-38, 38 Sr.
  • an isotope may be added to the reactant molecule.
  • radioactive isotopes in common use include iodine-125, 125 l; and iron-59, 59 Fe. Methods of radiolabeling reactants is well within the skill of the art.
  • intact Sf9 cells expressing high affinity hlL-5R are coupled to streptavidin-coated SPA beads using biotin-labeled peanut agglutinin (PNA).
  • Radiolabeled lL-5 and the sample to be tested e.g., for IL-5 antagonist activity or for the presence of IL-5) are added and binding of the radiolabeled reactant to the cells measured. Both direct and competitive assays are contemplated for use.
  • Direct assays are preferred when the assay is used to screen for IL- 5 antagonists. If an antagonist is present, less light is emitted.
  • a competitive assay may advantageously be used to quantitatively determine the amount of IL- 5 present in a sample. The non-labeled IL-5 in the sample competes with the labeled IL-5 for the receptors. The more IL-5 present in the sample, the less light is emitted.
  • the IL-5 receptor binding SPA can advantageously be performed in 96-well plates. Dimethyl sulfoxide (DMSO) concentrations up to 4% can be used. For the high through-put screening, test compounds are preferably dissolved in DMSO. In the scintillation proximity screening assay using PNA in accordance with the invention, the SPA has been unexpectedly found to be at least as sensitive as the filtration format receptor binding technique. Binding is specific for IL-5, and inhabitable by unlabeled IL-5 in a dose dependent manner.
  • DMSO dimethyl sulfoxide
  • the final plasmid which contained the human IL-5 receptor ⁇ chain cDNA insert (1.3 kb), was named pSRG5RFL.
  • p2Bac (7.1 kb), obtained from Invitrogen (Cat. No. V1980-10), served as a backbone for the recombinant baculovirus transfer vector of the invention.
  • p2Bac and pSRG5RFL were used to construct a transfer vector containing a DNA sequence encoding hlL-5R ⁇ (p2BaclL5R ⁇ ).
  • Both p2Bac and pSRG5RFL plasmids were initially digested, respectively, with a restriction enzyme EcoRI (Promega) under conditions suggested by the manufacturer.
  • EcoRI Promega
  • the 1.3 kb cDNA insert of human IL-5 receptor ⁇ -chain was isolated from the EcoRI digested pSRG5RFL after a gel- electrophoresis separation.
  • This cDNA insert was then ligated into the EcoRI digested p2Bac vector with a ligation kit (Cat. No. 203003, Stratagene) in accordance with the manufacturer's instructions.
  • the ligated DNA was then transformed into competent E. coli cells (MAX Efficiency DH5aTM Competent Cells, Cat. No.
  • the plasmids were isolated and purified from the bacterial cell with INSTA-MINI- PREPTM Kit (Cat. No. p1- 123456, 5 Prime-3 Prime, Inc.) and screened with Xba ⁇ digestions for the presence of the cDNA inserts and its orientation. After Xba ⁇ digestion, the plasmids that contains the 1.3 kb cDNA insert with the correct orientation gave rise to the both 7.7 kb and 0.69 kb DNA fragments illustrated on gel electrophoresis analysis.
  • the resultant plasmid containing the 1.3 kb cDNA insert with the correct orientation was then digested with a restriction enzyme, Ncol (Cat. No. 15421-019, GIBCOBRL) under conditions specified by the manufacturer.
  • Ncol a restriction enzyme
  • the Nco digested DNA was treated with mung bean nuclease (Cat. No. 18041-012, GIBCOBRL) under conditions suggested by the manufacturer to remove the single-stranded termini.
  • the purpose of this step was to remove a ATG (start codon) sequence that was localized at the immediate upstream region of the 1.3 cDNA insert. Therefore, the expression of the cDNA encoding protein will not be interfered by this start codon, ATG , in the final expression system.
  • the blunt-end linearized plasmid DNA was religated with the same ligation kit as described above and then transformed into the E. coli cells with the same commercially available competent cells as described above. The individual bacterial colonies were picked up and cultured as described above. The plasmids were extracted with the same kit and procedure as describe above and then screened with Ncol digestion. The plasmid that was not cut by Nco ⁇ was the final plasmid and was designated p2BaclL5R ⁇ .
  • D 2BaclL5RBi p2Bac was also used as a host vector to clone the cDNA insert of human IL-5 receptor ⁇ -chain.
  • the 3.0 kb cDNA insert of human IL-5 receptor ⁇ - chain was obtained from pKH97, prepared as described in Hayashida etal., (Proc. Natl. Acad. Sci. , (1990) 87:9655-9659).
  • the basic procedures and the kit used for DNA manipulations, transformations and bacterial cultures used to prepare p2BaclL5R ⁇ were identical to those used for the construction of p2BaclL5R ⁇ described above.
  • p2Bac was digested with the two restriction enzymes, Xba ⁇ and Smal (Promega) and the digested 7.1 kb fragment was then purified from the gel with the GENECLEAN II kit (Bio 101 Inc.) after the gel electrophoresis of the digested p2Bac.
  • pKH97 was subject to the digestion of restriction enzyme, Xho ⁇ (Promega), followed by blunting the end with the klenow fill-in kit (Cat. No. 200410, Stratagene) and its protocol. Then the Xhol digested pKH97 was further digested with two restriction enzyme Xba and Hindlll.
  • the 3.0 kb Xho ⁇ /Xbal digested fragment (human IL-5 receptor ⁇ cDNA) was purified from the gel with GENECLEAN II kit after the gel electrophoresis of the digested pKH97.
  • the 7.1 kb Xba/Sma digested p2Bac and 3.0 kb X o ⁇ /Xbal cDNA insert were mixed together and subject to ligation reaction with a ligation kit followed by transforming the ligated DNA into E coli cells.
  • the plasmids were purified from the mini-scale bacterial cultures and screened with restriction digestion using the enzymes Xbal and Bg1ll.
  • the plasmid that produced three fragments with the sizes of about 6.7, 2.1 and 1.28 , separately, after XballBglll digestion was retained and designated p2BaclL5R ⁇ .
  • This plasmid contains the cDNA insert of human IL-5 receptor ⁇ -chain with the correct orientation.
  • p2BaclL5R ⁇ was digested with the restriction enzymes BamHI and Hindlll (Promega) and the Ba HI/H/ ⁇ dlll digested 1.3 kb cDNA insert of hlL-5R ⁇ was isolated from gel after the gel electrophoresis.
  • p2BaclL5R ⁇ was also subject to the restriction digestions of BamHI and Hindlll and then the 10.3 kb digested fragment of hlL-5R ⁇ was isolated from the gel after gel electrophoresis.
  • the 1.3 kb cDNA insert was ligated with the 10.3 kb fragment in a DNA ligation reaction.
  • the ligated DNA was then transformed into E. coli cells.
  • the plasmids were purified from the mini-cultured bacterial cells and screened, separately, with either Xbal or EcoRI digestions.
  • the plasmjd containing both the ⁇ and ⁇ cDNA inserts with the correct orientations produced two Xbal digested fragments of 8.0 kb and 3.6 kb sizes, and generated two EcoRI digested fragments of 10.3 kb and 1.3 kb sizes.
  • One of these plasmids was retained and designated p2BaclL5R ⁇ .
  • the baculovirus transfer vector, p2BaclL5R ⁇ was used to generate the recombinant baculovirus containing both the ⁇ and ⁇ cDNA inserts.
  • Two recombinant bacuioviruses containing either the ⁇ cDNA insert or ⁇ cDNA insert were also generated following similar procedures by using transfer vectors p2BaclL5R ⁇ and p2BaclL5R ⁇ , respectively.
  • the recombinant bacuioviruses were generated by co-transfection of the wild type baculovirus (AcMNPV) DNA with the transfer vector p2BaclL5R ⁇ .
  • the presence of the cDNA insert at the locus of the polyhedrin gene of the AcMNPV baculoviral DNA in the recombinant bacuioviruses were verified by PCR analysis using a pair of primers specific to the sequences of the polyhedrin gene: Forward primer (-44) 5'-TTTA CTGT TTTC GTAA CAGT TTTG-3'; and Reverse primer (+778) 5'-CAAC AACG CACA GAAT CTAG-3' (SEQ ID NOS 1 and 2, respectively).
  • the recombinant baculoviral DNAs with the cDNA insert(s) Based on the distance between the two primers (734 bp) and the size of the ⁇ cDNA insert (1.3 kb), the recombinant baculoviral DNAs with the cDNA insert(s) generates a specific PCR product with the size of 2,034 kb using this pair of primers.
  • Viral DNAs of clones (designated as clones 2, 3 and 4) gave the specific DNA fragments, generated by PCR, suggesting that these viral clones were recombinant viruses containing at least the IL-5R ⁇ cDNA insert. These clones were therefore amplified for further characterization.
  • the PCR characterization of the recombinant viral genomes were performed by the custom baculovirus service group, Invitrogen Corporation. The PCR condition was as follows: 1 cycle of 2 minutes at 94 °C; 30 cycles of 1 minutes at 94 °C, 2 minutes at 55 C C and 3 minutes at 72 °C; 1 cycle of 7 minutes at 72 °C. Characterization of the Recombinant Bacuioviruses
  • Sf9 cells were seeded at 0.5 x 10 s cells ml and cultured at 27° C for 3 days in medium Sf-900 II SFM (GIBCOBRL, Cat. No. 10902-088) supplemented with 2 mM glutamine and 3% fetal bovine serum.
  • the cells at the concentration of 2 x 10* cells/ml, were infected with the recombinant viral clones 2, 3 and 4, separately. After the two-day infections, the cells were harvested and the total RNAs were extracted from the infected cells with TRISOLVTM RNA isolation kit (BIOTECX LABORATORIES, INC.) in accordance with the manufacture's instructions.
  • the total RNAs were subject to RT-PCR analysis using GeneAmp RNA kit (Perkin Elmer Cetus, Cat. No. N808-0017) following the manufacture's instructions.
  • RNAs were transcribed into the cDNA with the reverse transcriptase.
  • the PCR reactions were then carried out with the above cDNAs and the gene specific primers.
  • the primers for human IL-5 receptor ⁇ cDNA were: Forward primer (+499): 5'-AAGC AAAT GTGT AACC ATCC TCCA CAAA GG-3'; and Reverse primer (+1060): ⁇ '-AAAG CAAT GGAT TGGA AAAG CAGA CACT GG-3' (Clontech, Cat. No. 9203-1) (SEQ ID NOS 3 and 4, respectively). Therefore, the 561 -bp DNA fragments was used to show the correct PCR products specific to the mRNA of the ⁇ cDNA.
  • the primers for human IL-5 receptor ⁇ cDNA were: Forward primer (+1180): 5'-AAGG ACAG CAAG ACCG AGAC C-3'; and Reverse primer (+1930): 5'-CCCC CAGC AGGC AGAC ACAG G-3' (SEQ ID NOS 5 and 6, respectively).
  • Forward primer (+18): 5'-AAGG ACAG CAAG ACCG AGAC C-3'
  • Sf9 cells infected with viral clones 2 and 3 expressed both the ⁇ and ⁇ mRNA of human IL-5 receptor, based on the appearances of the specific PCR products described above.
  • viral clones 2 and 3 which contain both the ⁇ and ⁇ cDNA inserts, are the desired recombinant bacuioviruses.
  • Sf9 ceils infected with recombinant viral clone 2 was further characterized. RT-PCR analysis indicated that Sf9 cells infected with the recombinant viral clone 2 expressed the mRNAs specific to both the ⁇ and ⁇ cDNA inserts.
  • Western blot experiments were performed using antibodies specific to both the ⁇ and ⁇ proteins of hlL-5R to determine the protein expressions and their apparent sizes on SDS-PAGE gel.
  • the cells infected with clone 2 were harvested after one day infection and then lysed in SDS-gel loading buffer (62.5 mM Tris-HCl, pH 6.8/1% SDS/0.0025% bromphenol blue/2.5% 2- mercaptoethanol 10% glycerol) containing 5 M urea. Equal amounts of cell extracts were loaded on the gel and the proteins were resolved by electrophoresis on 8-16% polyacrylamide SDS minigels (Novex, San Diego). Then the proteins on the gel were electrophoretically transferred to nitrocellulose membranes. The membranes were blocked by overnight incubation at 4°C in PBS/5% dry milk/0.1% Tween-20.
  • a polyclonal rabbit IgG specific for the ⁇ chain of human IL-5 receptor was prepared using methods known in the art and used at 1:2500 dilution following a pre-incubation with non-infected Sf9 cell lysates for 1 hour.
  • the membranes were incubated for 1 hour at room temperature in 10 ml of PBS/1% fetal bovine serum/0.1% Tween-20/ 4 ⁇ l anti- ⁇ antibody.
  • the membranes were then incubated with a second antibody, HPR- labeled anti rabbit IgG (Amersham), at a 1:4000 dilution in 10 ml of PBS/0.1% Tween-20 for 1 hour after several washings.
  • the antibody was developed with ECL western blotting analysis system (Cat. No. RPN 2108; Amersham) and its protocols.
  • a mouse monoclonal IgG (0.1 mg/ml) specifically against the ⁇ chain protein was purchased from Santa Cruz Biotechnology, Inc (Cat. No. sc-457) was used in this study at a 1:400 dilution.
  • the remaining procedures for the ⁇ chain are similar to those used to detect the ⁇ chain except that the second antibody was HRP- labeled anti mouse IgG (Amersham) and used at a 1 :2000 dilution.
  • Sf9 cells were also infected with the same viral clone and infected cells harvested at several different time points to reveal the kinetic profiles of both the ⁇ and ⁇ chain expressions. It was found that the expression levels of the 60 kd ⁇ chain protein increased dramatically during the first two days of infection and then reached a steady-state level. In contrast, the profile of the ⁇ chain was very different. First, the expression of the full-length and mature 130 kDa protein took place and reached the peak on day two. Then the amount of 130 kDa protein began to decrease on day three and disappeared by day four. Meanwhile, two proteins with the smaller sizes were detected by the ⁇ -specific antibody on day two and their amounts were increased over the times of the infections.
  • the infected cells harvested in the time-course study described above were also used to perform receptor binding assays using 12S l-labeled human IL-5.
  • the cells were counted and harvested at several different time points.
  • the data of receptor binding, K value and binding sites/per cell were obtained with a filtration method. Table 1 shows the K d values and the binding sites per cell.
  • Recombinant viral clone 2 was used to prepare a high-titer viral stock for large-scale protein expressions.
  • High-titer viral stocks were prepared by as follows: 2 X 10 6 Sf9 cells were seeded in two T-25 tissue culture flasks in a total of 5 ml of media. 20 ⁇ l of the original viral stock were added to the flasks. Infection was allowed to proceed for 7-10 days, at which time the entire contents of the flasks were harvested. These were then used to infect 500 ml of Sf9 cells, which were at a density of 1.8 to 2.2 X 10 s cells/ml, and have a viability of greater than or equal to 98%. Infection was allowed to proceed 7-10 days.
  • the high titer stock was harvested when the cell lysis was greater than or equal to 90% as determined by trypan blue dye exclusion. The cell debris was pelleted and discarded, while the supernatant was removed and stored at 4 °C. The high titer stock was titered by a standard plaque assay procedure. The dilution used to titer the stock were 1:10* and 1 :10 7 . Large-Scale Expression of Hloh Affinity hlL-5R in Sf9 cells
  • Sf9 cells were cultured at 27 °C in 1 liter of the medium Sf-900 ll SFM (GIBCOBRL, Cat. No. 10902-088) supplemented with 2 mM glutamine and 3% fetal bovine serum until the cell density was 2.0 x 10 6 cells/ml and viability was at least 98%. Then the cells were precipitated down and resuspended in 1 liter of the fresh medium. The expressions were carried out by the infection of Sf9 cells with the high titer stock of the recombinant viral clone 2 at a MOI (Multiplicity of infection) of 5. After two days, the infected Sf9 cells were harvested and characterized by IL-5 receptor binding assays.
  • MOI Multiplicity of infection
  • the S19 cells were cultured in their specific condition and 1 liter Sf9 cells with the density of 4 x 10 6 cells/ml were infected with the high titer stock of the recombinant viral clone 2 at an MOI of 2 for two days.
  • the infected cells were harvested and characterized by IL-5 receptor binding assays.
  • the expressions of human IL-5 receptors by each of these protocols were very similar regarding the binding affinity and receptor number per cell.
  • the assay is performed in 96-well microtiter plates. Assay mixtures, in a total volume of 200 ⁇ l, were prepared which contained 30,000 cells, 100,000 cpm of [ 125 l]IL-5, 0.125 mg of streptavidin-SPA beads, 0.6 ⁇ g of biotin-PNA, the compound to be tested or unlabeled IL-5 at various concentrations (as positive control for inhibition of the binding), in a buffer consisting of 50 mM Tris-HCl, pH 7.4, 2 mM EGTA, 3 mM MgCI 2 , 1 mM Pefabloc SC, 10 ⁇ gml leupeptin, 2 ⁇ g/ml aprotinin, 0.12 M NaCl, 0.1% BSA, 0.01% NaN3 and 0.75% gelatin.
  • Assay mixtures in a total volume of 200 ⁇ l, were prepared which contained 30,000 cells, 100,000 cpm of [ 125 l]IL-5, 0.125 mg of streptavidin-SPA beads
  • the cells are first incubated with unlabeled IL-5 or the test compound at room temperature for 15 minutes with shaking, followed by addition of [ 125 l]IL-5. After incubation at room temperature for 10 minutes with shaking, the SPA beads mixed with biotin-PNA is added. The mixture is incubated at room temperature for 18-24 hours with shaking, then the radioactivity is directly counted in a ⁇ -counter. Under these conditions, total IL-5 binding (in the absence of unlabeled IL-5 or other binding inhibitors) is about 2000-3500 cpm, and non-specific binding (in the presence of 500-fold unlabeled IL-5) is 110-120 cpm. The binding is specific for IL-5, and inhibitable by unlabeled IL-5 in a dose dependent manner with an IC50 of about 200 pM.

Abstract

Linvention concerne un système d'expression baculovirus/cellule d'insecte permettant une surexpression des sous-unités α et β du récepteur humain de l'IL-5, dans la lignée cellulaire Sf9. Ce système est capable d'exprimer des récepteurs d'IL-5 humains à haute affinité, à des concentrations très élevées. Il peut être utilisé dans un dosage de criblage d'antagonistes des récepteurs humains de l'IL-5. Le dosage de criblage préféré consiste en un dosage de proximité par scintillation, avec une agglutinine d'arachide utilisée comme lectine.
PCT/US1997/000011 1996-01-17 1997-01-15 Systeme faisant appel a un baculovirus pour l'expression d'un recepteur de l'interleukine 5 humaine et methode de criblage d'antagonistes de l'interleukine 5 WO1997026332A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU16906/97A AU1690697A (en) 1996-01-17 1997-01-15 Baculovirus expression system for human interleukin 5 receptor and method of screening for interleukin antagonists

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US1014196P 1996-01-17 1996-01-17
US60/010,141 1996-01-17
US58879596A 1996-01-19 1996-01-19
US08/588,795 1996-01-19

Publications (1)

Publication Number Publication Date
WO1997026332A1 true WO1997026332A1 (fr) 1997-07-24

Family

ID=26680833

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/000011 WO1997026332A1 (fr) 1996-01-17 1997-01-15 Systeme faisant appel a un baculovirus pour l'expression d'un recepteur de l'interleukine 5 humaine et methode de criblage d'antagonistes de l'interleukine 5

Country Status (2)

Country Link
AU (1) AU1690697A (fr)
WO (1) WO1997026332A1 (fr)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005085866A1 (fr) * 2004-02-27 2005-09-15 Novartis Ag Essai de criblage de modulateurs de l'interaction entre l'interleukine 12 et/ou l'interleukine 23 et ses/leurs recepteurs
WO2006069246A2 (fr) 2004-12-22 2006-06-29 Ambrx, Inc. Compositions contenant des acides amines non naturels et des polypeptides, procedes impliquant ces acides amines non naturels et polypeptides, et utilisations desdits acides amines non naturels et polypeptides
WO2008030558A2 (fr) 2006-09-08 2008-03-13 Ambrx, Inc. Polypeptide plasmatique humain modifié ou squelettes de fc et leurs utilisations
WO2009067636A2 (fr) 2007-11-20 2009-05-28 Ambrx, Inc. Polypeptides d'insuline modifiés et leurs utilisations
WO2010011735A2 (fr) 2008-07-23 2010-01-28 Ambrx, Inc. Polypeptides g-csf bovins modifiés et leurs utilisations
WO2010037062A1 (fr) 2008-09-26 2010-04-01 Ambrx, Inc. Vaccins et micro-organismes dépendant de la réplication d'acide aminé non naturels
US7736872B2 (en) 2004-12-22 2010-06-15 Ambrx, Inc. Compositions of aminoacyl-TRNA synthetase and uses thereof
US7816320B2 (en) 2004-12-22 2010-10-19 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35
EP2284191A2 (fr) 2004-12-22 2011-02-16 Ambrx, Inc. Procédé de préparation de hGH
US7947473B2 (en) 2004-12-22 2011-05-24 Ambrx, Inc. Methods for expression and purification of pegylated recombinant human growth hormone containing a non-naturally encoded keto amino acid
EP2327724A2 (fr) 2004-02-02 2011-06-01 Ambrx, Inc. Polypeptides d'hormone de croissance humaine et leur utilisations
US8012931B2 (en) 2007-03-30 2011-09-06 Ambrx, Inc. Modified FGF-21 polypeptides and their uses
US8093356B2 (en) 2005-06-03 2012-01-10 Ambrx, Inc. Pegylated human interferon polypeptides
US8114630B2 (en) 2007-05-02 2012-02-14 Ambrx, Inc. Modified interferon beta polypeptides and their uses
WO2012024452A2 (fr) 2010-08-17 2012-02-23 Ambrx, Inc. Polypeptides de relaxine modifiés et leurs utilisations
US8278418B2 (en) 2008-09-26 2012-10-02 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
US8420792B2 (en) 2006-09-08 2013-04-16 Ambrx, Inc. Suppressor tRNA transcription in vertebrate cells
EP2805965A1 (fr) 2009-12-21 2014-11-26 Ambrx, Inc. Polypeptides modifiés de somatotrophine bovine et leurs utilisations
EP2805964A1 (fr) 2009-12-21 2014-11-26 Ambrx, Inc. Polypeptides modifiés de somatotrophine bovine et leurs utilisations
US9133495B2 (en) 2006-09-08 2015-09-15 Ambrx, Inc. Hybrid suppressor tRNA for vertebrate cells
US9175083B2 (en) 2004-06-18 2015-11-03 Ambrx, Inc. Antigen-binding polypeptides and their uses
US9434778B2 (en) 2014-10-24 2016-09-06 Bristol-Myers Squibb Company Modified FGF-21 polypeptides comprising an internal deletion and uses thereof
US9488660B2 (en) 2005-11-16 2016-11-08 Ambrx, Inc. Methods and compositions comprising non-natural amino acids
EP3103880A1 (fr) 2008-02-08 2016-12-14 Ambrx, Inc. Polypeptides d'insuline modifiés et utilisations de ceux-ci
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
US10266578B2 (en) 2017-02-08 2019-04-23 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
US11273202B2 (en) 2010-09-23 2022-03-15 Elanco Us Inc. Formulations for bovine granulocyte colony stimulating factor and variants thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0492214A2 (fr) * 1990-12-27 1992-07-01 F. Hoffmann-La Roche Ag Récepteur humain de l'interleukine 5
EP0533006A1 (fr) * 1991-09-18 1993-03-24 F.Hoffmann-La Roche & Co. Aktiengesellschaft Chimères constituées du récepteur de l'interleukine 5 et de polypeptides d'immunoglobulines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0492214A2 (fr) * 1990-12-27 1992-07-01 F. Hoffmann-La Roche Ag Récepteur humain de l'interleukine 5
EP0533006A1 (fr) * 1991-09-18 1993-03-24 F.Hoffmann-La Roche & Co. Aktiengesellschaft Chimères constituées du récepteur de l'interleukine 5 et de polypeptides d'immunoglobulines

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BROWN PM ET AL: "A single-step purification of biologically active recombinant human interleukin-5 from a baculovirus expression system.", PROTEIN EXPR PURIF, FEB 1995, 6 (1) P63-71, UNITED STATES, XP000671245 *
BROWN PM ET AL: "Epitope-labeled soluble human interleukin-5 (IL-5) receptors. Affinity cross-link labeling, IL-5 binding, and biological activity.", J BIOL CHEM, DEC 8 1995, 270 (49) P29236-43, UNITED STATES, XP002029542 *

Cited By (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2327724A2 (fr) 2004-02-02 2011-06-01 Ambrx, Inc. Polypeptides d'hormone de croissance humaine et leur utilisations
US8907064B2 (en) 2004-02-02 2014-12-09 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
US8906676B2 (en) 2004-02-02 2014-12-09 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
US8232371B2 (en) 2004-02-02 2012-07-31 Ambrx, Inc. Modified human interferon polypeptides and their uses
US8097702B2 (en) 2004-02-02 2012-01-17 Ambrx, Inc. Modified human interferon polypeptides with at least one non-naturally encoded amino acid and their uses
US9260472B2 (en) 2004-02-02 2016-02-16 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
WO2005085866A1 (fr) * 2004-02-27 2005-09-15 Novartis Ag Essai de criblage de modulateurs de l'interaction entre l'interleukine 12 et/ou l'interleukine 23 et ses/leurs recepteurs
US9175083B2 (en) 2004-06-18 2015-11-03 Ambrx, Inc. Antigen-binding polypeptides and their uses
EP2399893A2 (fr) 2004-12-22 2011-12-28 Ambrx, Inc. Compositions contenant des acides aminés et des polypeptides non naturels, procédés les impliquant et leurs utilisations
US7829310B2 (en) 2004-12-22 2010-11-09 Ambrx, Inc. Compositions of aminoacyl-tRNA synthetase and uses thereof
US7846689B2 (en) 2004-12-22 2010-12-07 Ambrx, Inc. Compositions of aminoacyl-tRNA synthetase and uses thereof
US7858344B2 (en) 2004-12-22 2010-12-28 Ambrx, Inc. Compositions of aminoacyl-tRNA synthetase and uses thereof
US7883866B2 (en) 2004-12-22 2011-02-08 Ambrx, Inc. Compositions of aminoacyl-tRNA synthetase and uses thereof
EP2284191A2 (fr) 2004-12-22 2011-02-16 Ambrx, Inc. Procédé de préparation de hGH
US8178494B2 (en) 2004-12-22 2012-05-15 Ambrx, Inc. Modified human growth hormone formulations with an increased serum half-life
US7939496B2 (en) 2004-12-22 2011-05-10 Ambrx, Inc. Modified human growth horomone polypeptides and their uses
US7947473B2 (en) 2004-12-22 2011-05-24 Ambrx, Inc. Methods for expression and purification of pegylated recombinant human growth hormone containing a non-naturally encoded keto amino acid
US8143216B2 (en) 2004-12-22 2012-03-27 Ambrx, Inc. Modified human growth hormone
US7959926B2 (en) 2004-12-22 2011-06-14 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone mutants
US7838265B2 (en) 2004-12-22 2010-11-23 Ambrx, Inc. Compositions of aminoacyl-tRNA synthetase and uses thereof
US8178108B2 (en) 2004-12-22 2012-05-15 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone
US8163695B2 (en) 2004-12-22 2012-04-24 Ambrx Formulations of human growth hormone comprising a non-naturally encoded amino acid
US8080391B2 (en) 2004-12-22 2011-12-20 Ambrx, Inc. Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer
US7816320B2 (en) 2004-12-22 2010-10-19 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35
WO2006069246A2 (fr) 2004-12-22 2006-06-29 Ambrx, Inc. Compositions contenant des acides amines non naturels et des polypeptides, procedes impliquant ces acides amines non naturels et polypeptides, et utilisations desdits acides amines non naturels et polypeptides
US7736872B2 (en) 2004-12-22 2010-06-15 Ambrx, Inc. Compositions of aminoacyl-TRNA synthetase and uses thereof
US8093356B2 (en) 2005-06-03 2012-01-10 Ambrx, Inc. Pegylated human interferon polypeptides
US9488660B2 (en) 2005-11-16 2016-11-08 Ambrx, Inc. Methods and compositions comprising non-natural amino acids
US8420792B2 (en) 2006-09-08 2013-04-16 Ambrx, Inc. Suppressor tRNA transcription in vertebrate cells
US8053560B2 (en) 2006-09-08 2011-11-08 Ambrx, Inc. Modified human plasma polypeptide or Fc scaffolds and their uses
US8022186B2 (en) 2006-09-08 2011-09-20 Ambrx, Inc. Modified human plasma polypeptide or Fc scaffolds and their uses
US7919591B2 (en) 2006-09-08 2011-04-05 Ambrx, Inc. Modified human plasma polypeptide or Fc scaffolds and their uses
US9133495B2 (en) 2006-09-08 2015-09-15 Ambrx, Inc. Hybrid suppressor tRNA for vertebrate cells
WO2008030558A2 (fr) 2006-09-08 2008-03-13 Ambrx, Inc. Polypeptide plasmatique humain modifié ou squelettes de fc et leurs utilisations
US8618257B2 (en) 2006-09-08 2013-12-31 Ambrx, Inc. Modified human plasma polypeptide or Fc scaffolds and their uses
US8012931B2 (en) 2007-03-30 2011-09-06 Ambrx, Inc. Modified FGF-21 polypeptides and their uses
US10377805B2 (en) 2007-03-30 2019-08-13 Ambrx, Inc. Modified FGF-21 polypeptides comprising non-naturally encoding amino acids and their uses
US8383365B2 (en) 2007-03-30 2013-02-26 Ambrx, Inc. Methods of making FGF-21 mutants comprising non-naturally encoded phenylalanine derivatives
US9975936B2 (en) 2007-03-30 2018-05-22 Ambrx, Inc. Nucleic acids encoding modified FGF-21 polypeptides comprising non-naturally occurring amino acids
US9079971B2 (en) 2007-03-30 2015-07-14 Ambrx, Inc. Modified FGF-21 polypeptides comprising non-naturally occurring amino acids
US9517273B2 (en) 2007-03-30 2016-12-13 Ambrx, Inc. Methods of treatment using modified FGF-21 polypeptides comprising non-naturally occurring amino acids
US10961291B2 (en) 2007-03-30 2021-03-30 Ambrx, Inc. Modified FGF-21 polypeptides and their uses
US8114630B2 (en) 2007-05-02 2012-02-14 Ambrx, Inc. Modified interferon beta polypeptides and their uses
WO2009067636A2 (fr) 2007-11-20 2009-05-28 Ambrx, Inc. Polypeptides d'insuline modifiés et leurs utilisations
EP2930182A1 (fr) 2007-11-20 2015-10-14 Ambrx, Inc. Polypeptides d'insuline modifiés et utilisations de ceux-ci
US8946148B2 (en) 2007-11-20 2015-02-03 Ambrx, Inc. Modified insulin polypeptides and their uses
US9938333B2 (en) 2008-02-08 2018-04-10 Ambrx, Inc. Modified leptin polypeptides and their uses
EP3103880A1 (fr) 2008-02-08 2016-12-14 Ambrx, Inc. Polypeptides d'insuline modifiés et utilisations de ceux-ci
EP3225248A1 (fr) 2008-07-23 2017-10-04 Ambrx, Inc. Polypeptides g-csf bovins modifiés et leurs utilisations
US10138283B2 (en) 2008-07-23 2018-11-27 Ambrx, Inc. Modified bovine G-CSF polypeptides and their uses
WO2010011735A2 (fr) 2008-07-23 2010-01-28 Ambrx, Inc. Polypeptides g-csf bovins modifiés et leurs utilisations
US9644014B2 (en) 2008-09-26 2017-05-09 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
US8569233B2 (en) 2008-09-26 2013-10-29 Eli Lilly And Company Modified animal erythropoietin polypeptides and their uses
WO2010037062A1 (fr) 2008-09-26 2010-04-01 Ambrx, Inc. Vaccins et micro-organismes dépendant de la réplication d'acide aminé non naturels
US9156899B2 (en) 2008-09-26 2015-10-13 Eli Lilly And Company Modified animal erythropoietin polypeptides and their uses
US9121024B2 (en) 2008-09-26 2015-09-01 Ambrx, Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
US9121025B2 (en) 2008-09-26 2015-09-01 Ambrx, Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
US10428333B2 (en) 2008-09-26 2019-10-01 Ambrx Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
US8278418B2 (en) 2008-09-26 2012-10-02 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
EP3216800A1 (fr) 2008-09-26 2017-09-13 Ambrx, Inc. Polypeptides d'érythropoïétine animale modifiés et leurs utilisations
EP2805964A1 (fr) 2009-12-21 2014-11-26 Ambrx, Inc. Polypeptides modifiés de somatotrophine bovine et leurs utilisations
EP2805965A1 (fr) 2009-12-21 2014-11-26 Ambrx, Inc. Polypeptides modifiés de somatotrophine bovine et leurs utilisations
US10751391B2 (en) 2010-08-17 2020-08-25 Ambrx, Inc. Methods of treatment using modified relaxin polypeptides comprising a non-naturally encoded amino acid
US8735539B2 (en) 2010-08-17 2014-05-27 Ambrx, Inc. Relaxin polypeptides comprising non-naturally encoded amino acids
EP4302783A2 (fr) 2010-08-17 2024-01-10 Ambrx, Inc. Polypeptides de relaxine modifiés et leurs utilisations
US11786578B2 (en) 2010-08-17 2023-10-17 Ambrx, Inc. Modified relaxin polypeptides and their uses
US10253083B2 (en) 2010-08-17 2019-04-09 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
US11439710B2 (en) 2010-08-17 2022-09-13 Ambrx, Inc. Nucleic acids encoding modified relaxin polypeptides
US11311605B2 (en) 2010-08-17 2022-04-26 Ambrx, Inc. Methods of treating heart failure and fibrotic disorders using modified relaxin polypeptides
WO2012024452A2 (fr) 2010-08-17 2012-02-23 Ambrx, Inc. Polypeptides de relaxine modifiés et leurs utilisations
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
US10702588B2 (en) 2010-08-17 2020-07-07 Ambrx, Inc. Modified relaxin polypeptides comprising a non-naturally encoded amino acid in the A chain
US9962450B2 (en) 2010-08-17 2018-05-08 Ambrx, Inc. Method of treating heart failure with modified relaxin polypeptides
US9452222B2 (en) 2010-08-17 2016-09-27 Ambrx, Inc. Nucleic acids encoding modified relaxin polypeptides
US11273202B2 (en) 2010-09-23 2022-03-15 Elanco Us Inc. Formulations for bovine granulocyte colony stimulating factor and variants thereof
US9434778B2 (en) 2014-10-24 2016-09-06 Bristol-Myers Squibb Company Modified FGF-21 polypeptides comprising an internal deletion and uses thereof
US11248031B2 (en) 2014-10-24 2022-02-15 Bristol-Myers Squibb Company Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides
US10377806B2 (en) 2014-10-24 2019-08-13 Bristol-Myers Squibb Company Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides and uses thereof
US10189883B2 (en) 2014-10-24 2019-01-29 Bristol-Myers Squibb Company Therapeutic uses of modified FGF-21 polypeptides
US9631004B2 (en) 2014-10-24 2017-04-25 Bristol-Myers Squibb Company Modified FGF-21 polypeptides comprising an internal deletion and uses thereof
US11185570B2 (en) 2017-02-08 2021-11-30 Bristol-Myers Squibb Company Method of treating cardiovascular disease and heart failure with modified relaxin polypeptides
US11364281B2 (en) 2017-02-08 2022-06-21 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereof
US10266578B2 (en) 2017-02-08 2019-04-23 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof

Also Published As

Publication number Publication date
AU1690697A (en) 1997-08-11

Similar Documents

Publication Publication Date Title
US5861279A (en) Baculovirus expression system for human interleukin 5 receptor and method of screening for interleukin 5 antagonists
WO1997026332A1 (fr) Systeme faisant appel a un baculovirus pour l'expression d'un recepteur de l'interleukine 5 humaine et methode de criblage d'antagonistes de l'interleukine 5
Stoecklin et al. Functional cloning of BRF1, a regulator of ARE-dependent mRNA turnover
Azam et al. Functionally distinct isoforms of STAT5 are generated by protein processing
Skoda et al. Murine c‐mpl: a member of the hematopoietic growth factor receptor superfamily that transduces a proliferative signal.
Owman et al. Cloning of human cDNA encoding a novel heptahelix receptor expressed in Burkitt's lymphoma and widely distributed in brain and peripheral tissues
Lee et al. A baculovirus superinfection system: efficient vehicle for gene transfer into Drosophila S2 cells
KR19980041692A (ko) 신규한 에스트로겐 수용체
Sautter et al. Selection of high‐producing CHO cells using NPT selection marker with reduced enzyme activity
PT566554E (pt) Producao de proteinas recombinantes usando promotores do virus de herpes e transactivadores vp16
AU5117399A (en) Substantially complete ribozyme libraries
Gadeau et al. Induction of cell cycle‐dependent genes during cell cycle progression of arterial smooth muscle cells in culture
Junker et al. Both immunoglobulin promoter and enhancer sequences are targets for suppression in myeloma‐fibroblast hybrid cells.
JPH05236965A (ja) ｔｒｋＣタンパク質
US8309700B2 (en) Inhibitor of histone acetyltransferase, especially p300
US20030170784A1 (en) Secreted proteins and uses thereof
WO2000050633A1 (fr) Procede de clonage de produits intermediaires de transduction de signaux
RU2139936C1 (ru) Способ определения модулирующего действия вещества на зависимый от рецептора интерлейкина-5 путь передачи сигналов в человеческой клетке или клетке животного
Krüger et al. [12] Use of ribozymes to inhibit gene expression
JP2000201688A (ja) エストロジェンレセプタ―遺伝子およびその利用
Baust et al. Functional activity of HERV-K-T47D-related long terminal repeats
CA2315242C (fr) Clonage non bacterien pour l'apport et l'expression d'acides nucleiques
EP0765402A1 (fr) Regulation du recepteur d'estrogenes et son utilisation
US20030054389A1 (en) Methods for identifying agents that induce a cellular phenotype, and compositions thereof
US20030054002A1 (en) Isolation of genes within SLE-1B that mediate a break in immune tolerance

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CZ EE GE HU IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ TM TR TT UA UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97526018

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase